The China-based trial enrolled 398 patients who were randomised to the ivonescimab and Keytruda arms at a one-to-one ratio.

Summit Therapeutics acquired rights to ivonescimab outside of China and Australia. With Keytruda sales up around $25 billion ...

Summit Therapeutics’ ivonescimab has the potential to challenge Merck’s blockbuster checkpoint inhibitor in non-small cell ...

Better-than-expected trial data means Summit's bispecific antibody could replace the blockbuster Keytruda as a standard of ...

Merck and Daiichi Sankyo's HER3 antibody-drug conjugate reported a positive phase 3 result in EGFR-mutated lung cancer. Merck ...

In head-to-head clinical trial, Chinese firm Akeso’s ivonescimab beat top-selling drug pembrolizumab sold as Keytruda by Merck. Ivonescimab reduced risk of tumour progression by 49%.

Keytruda is an antibody that binds to programmed death receptors (PD-1) on the surface of immune cells. This checkpoint is supposed to keep those cells from destroying healthy tissue, but tumor ...

Summit Therapeutics (SMMT) boost Instil Bio (TIL) and BioNTech (BNTX) as its PD-1/VEGF bispecific antibody outperforms ...

Incyte’s late PD-1 entrant Zynyz has chalked up a unique clinical win. | Incyte’s late PD-1 entrant Zynyz has chalked up a ...